Stockscreener 앱 받기
6.23
6.32%
-0.42
시장 영업 전:
6.66
0.43
+6.90%
전일 마감가:
$6.65
열려 있는:
$6.59
하루 거래량:
1.56M
Relative Volume:
1.99
시가총액:
$336.90M
수익:
$8.78M
순이익/손실:
$-104.70M
주가수익비율:
-2.6287
EPS:
-2.37
순현금흐름:
$-82.68M
1주 성능:
-19.51%
1개월 성능:
-20.64%
6개월 성능:
-49.64%
1년 성능:
-53.82%
1일 변동 폭
$6.10
$6.73
1주일 범위
$6.10
$7.74
52주 변동 폭
$6.10
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
STOK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
6.23 | 336.90M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - Business Wire
Revolutionary RNA Treatment for Rare Disease: Stoke CEO to Reveal Latest Progress - Stock Titan
Swiss National Bank Acquires 11,400 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
FY2025 Earnings Forecast for STOK Issued By Chardan Capital - Defense World
Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges By Investing.com - Investing.com South Africa
Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges - Investing.com
Dravet Syndrome Market Expected to Experience Major Growth - openPR.com
Bank of New York Mellon Corp Acquires 1,330 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
(STOK) Technical Data - news.stocktradersdaily.com
Cantor Fitzgerald Issues Positive Forecast for STOK Earnings - Defense World
Wedbush Equities Analysts Raise Earnings Estimates for STOK - Armenian Reporter
Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Brokers Offer Predictions for STOK Q3 Earnings - Defense World
What is Leerink Partnrs’ Forecast for STOK Q1 Earnings? - Defense World
Q1 EPS Estimates for Stoke Therapeutics Increased by Wedbush - Defense World
Stoke Therapeutics general counsel sells shares totaling $35,731 By Investing.com - Investing.com South Africa
Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Chardan Capital - Defense World
Stoke Therapeutics (NASDAQ:STOK) Earns “Buy” Rating from HC Wainwright - Defense World
Analysts Issue Forecasts for STOK Q1 Earnings - Defense World
Stoke therapeutics’ chief medical officer sells $61,238 in stock By Investing.com - Investing.com South Africa
Stoke Therapeutics general counsel sells shares totaling $35,731 - Investing.com
Stoke Therapeutics director Kaye Edward M. sells shares worth $163,672 - Investing.com
Stoke therapeutics’ chief medical officer sells $61,238 in stock - Investing.com India
Stoke Therapeutics Executives Sell Shares for Tax Liabilities - TradingView
Stoke Therapeutics director Kaye Edward M. sells shares worth $163,672 By Investing.com - Investing.com UK
The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - Medical Marketing and Media
After Securing Biogen Pact, Stoke’s CEO Edward Kaye Bows Out - insights.citeline.com
Stoke Therapeutics announces CEO transition - The Pharma Letter
Stoke Therapeutics Inc (STOK) Q4 Earnings: EPS of -$0.18 Beats E - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC - Defense World
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS) and Stoke Therapeutics (STOK) - The Globe and Mail
Stoke Therapeutics, Inc. SEC 10-K Report - TradingView
Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics - Benzinga
Ed Kaye, founding CEO of Stoke Therapeutics, steps down - The Business Journals
Stoke Therapeutics Slips as CEO Steps Down - MSN
Stoke Therapeutics falls as CEO steps down amid earnings beat By Investing.com - Investing.com Canada
Stoke Therapeutics falls as CEO steps down amid earnings beat - Investing.com India
Stoke CEO Ed Kaye to depart shortly after inking Biogen pact and before its first Phase 3 trial - Endpoints News
Stoke Therapeutics CEO Edward Kaye Steps Down; Interim CEO Named -March 18, 2025 at 08:02 am EDT - MarketScreener
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Stoke Therapeutics appoints interim CEO amid leadership shuffle - Investing.com
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - BioSpace
Stoke Therapeutics Announces 2024 Financial Results and Updates - TipRanks
Stoke Therapeutics Appoints Director Ian F. Smith Interim Chief Executive Officer -March 18, 2025 at 06:59 am EDT - Marketscreener.com
Stoke Therapeutics Inc Q4 Loss Decreases, Beats Estimates - Nasdaq
Stoke Therapeutics earnings beat by $0.37, revenue topped estimates - Investing.com UK
Stoke Therapeutics Announces CEO Transition - Business Wire
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Stoke Therapeutics (STOK) to Release Quarterly Earnings on Monday - Defense World
Rhumbline Advisers Acquires 2,787 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.89%
0.13%
자본화:
|
볼륨(24시간):